Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other financing activities (2023 - 2025)

Historic Other financing activities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $8.6 million.

  • Compass Therapeutics' Other financing activities rose 43180000.0% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 286769.76%. This contributed to the annual value of $543000.0 for FY2024, which is 44150.94% up from last year.
  • Compass Therapeutics' Other financing activities amounted to $8.6 million in Q3 2025, which was up 43180000.0% from -$2000.0 recorded in Q4 2024.
  • In the past 5 years, Compass Therapeutics' Other financing activities registered a high of $8.6 million during Q3 2025, and its lowest value of -$254000.0 during Q4 2023.
  • In the last 3 years, Compass Therapeutics' Other financing activities had a median value of $500.0 in 2024 and averaged $1.5 million.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 9921.26% in 2024, then surged by 43180000.0% in 2025.
  • Over the past 3 years, Compass Therapeutics' Other financing activities (Quarter) stood at -$254000.0 in 2023, then surged by 99.21% to -$2000.0 in 2024, then soared by 432000.0% to $8.6 million in 2025.
  • Its Other financing activities stands at $8.6 million for Q3 2025, versus -$2000.0 for Q4 2024 and $2000.0 for Q3 2024.